NASDAQ Capital Marke • Healthcare • Biotechnology • IE • USD
Iterum Therapeutics plc (ITRM) has a consensus analyst rating of Hold, based on 1 analyst covering the stock. Of those, 0 recommend buying, 1 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
